A portrait of research participant Amber wearing a gray-blue sweater and standing beside a brick wall
Participant Spotlight

Immunotherapy proven to slow T1D progression in people newly diagnosed now being tested for prevention

Amber Van Den Heuvel received low-dose anti-thymocyte globulin (ATG) in 2015 as a participant in a TrialNet clinical study for people newly diagnosed with type 1 diabetes (T1D). Five years later, she still had beta cell function. Today, at age 26, Amber is encouraging people at high risk for T1D to consider participating in a TrialNet prevention study using the same therapy.

Read more
Raised hands appear from the bottom of the image with the text "HELP US STOP-T1D". The background of the image is pale green and contains Y-shaped autoantibodies arranged into the shape of a stop sign.
Research Spotlight

New prevention study now open for enrollment – Help us find out if a low dose immunotherapy can STOP-T1D

TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years. 

Read more
Subscribe to STOP-T1D Study